在医疗条件有限的情况下使用降血脂药物:土耳其 COVID-19 大流行期间药物使用趋势(PANDUTI-TR)研究结果。

IF 3.5 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Caner Vizdiklar , Volkan Aydin , Gokhan Tazegul , Mert Kaskal , Ahmet Akici
{"title":"在医疗条件有限的情况下使用降血脂药物:土耳其 COVID-19 大流行期间药物使用趋势(PANDUTI-TR)研究结果。","authors":"Caner Vizdiklar ,&nbsp;Volkan Aydin ,&nbsp;Gokhan Tazegul ,&nbsp;Mert Kaskal ,&nbsp;Ahmet Akici","doi":"10.1016/j.vph.2024.107382","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>COVID-19 restrictions prompted changes in chronic disease management and lifestyle modifications, potentially altering cardiometabolic indicators and lipid-lowering pharmacotherapy patterns. We aimed to assess lipid-lowering drug (LLD) utilization trends during COVID-19 restrictions.</p></div><div><h3>Methods</h3><p>We obtained nationwide outpatient drug sales and prescribing data for 01.03.2018–31.12.2022 from IQVIA™ Turkey. We evaluated average monthly LLD consumption, their costs, and quarterly prescribing levels in three periods: “before restrictions” (BfR, 01.03.2018–31.03.2020), “during restrictions” (DuR, 01.04.2020–31.03.2022), and “after restrictions” (AfR, 01.04.2022–31.12.2022). Drug utilization was measured via “defined daily dose/1000 inhabitants/day” (DID) metric.</p></div><div><h3>Results</h3><p>LLD utilization increased from 25.4 ± 3.1 DID in BfR to 36.2 ± 6.8 DID in DuR (<em>p</em> &lt; 0.001), and to 42.6 ± 5.3 DID in AfR (<em>p</em> &lt; 0.001 vs. BfR). Statin consumption significantly rose from 22.0 ± 3.0 DID in BfR to 31.6 ± 6.3 DID in DuR (<em>p</em> &lt; 0.001), and further to 37.6 ± 4.7 DID in AfR (<em>p</em> &lt; 0.01 vs. DuR). High-intensity statin consumption elevated by 115.9% in AfR compared to baseline (<em>p</em> &lt; 0.001). Prescribing of LLDs decreased from 12.5 ± 0.6 DID in BfR to 7.2 ± 1.2 DID in DuR (<em>p</em> &lt; 0.001), later reached 13.6 ± 3.8 DID in AfR (<em>p</em> &lt; 0.001 vs. DuR), with prescribing for ongoing users following similar trend. Expenditure on LLDs increased from €8.4 m ± 0.9 m in BfR to €11.4 m ± 2.0 m in DuR (<em>p</em> &lt; 0.001) and to €12.8 m ± 1.9 m in AfR (<em>p</em> &lt; 0.001 vs. BfR).</p></div><div><h3>Conclusions</h3><p>This study revealed a surge in consumption of LLDs in Turkey following the onset of the COVID-19 pandemic. This rise might be related to practices facilitating drug access, in addition to potentially greater adherence, or the necessity for more intense pharmacotherapy due to elevated cardiovascular risk.</p></div>","PeriodicalId":23949,"journal":{"name":"Vascular pharmacology","volume":null,"pages":null},"PeriodicalIF":3.5000,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Use of lipid-lowering drugs in restricted health access settings: Results from the Trends in Drug Utilization During COVID-19 Pandemic in Turkey (PANDUTI-TR) study\",\"authors\":\"Caner Vizdiklar ,&nbsp;Volkan Aydin ,&nbsp;Gokhan Tazegul ,&nbsp;Mert Kaskal ,&nbsp;Ahmet Akici\",\"doi\":\"10.1016/j.vph.2024.107382\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>COVID-19 restrictions prompted changes in chronic disease management and lifestyle modifications, potentially altering cardiometabolic indicators and lipid-lowering pharmacotherapy patterns. We aimed to assess lipid-lowering drug (LLD) utilization trends during COVID-19 restrictions.</p></div><div><h3>Methods</h3><p>We obtained nationwide outpatient drug sales and prescribing data for 01.03.2018–31.12.2022 from IQVIA™ Turkey. We evaluated average monthly LLD consumption, their costs, and quarterly prescribing levels in three periods: “before restrictions” (BfR, 01.03.2018–31.03.2020), “during restrictions” (DuR, 01.04.2020–31.03.2022), and “after restrictions” (AfR, 01.04.2022–31.12.2022). Drug utilization was measured via “defined daily dose/1000 inhabitants/day” (DID) metric.</p></div><div><h3>Results</h3><p>LLD utilization increased from 25.4 ± 3.1 DID in BfR to 36.2 ± 6.8 DID in DuR (<em>p</em> &lt; 0.001), and to 42.6 ± 5.3 DID in AfR (<em>p</em> &lt; 0.001 vs. BfR). Statin consumption significantly rose from 22.0 ± 3.0 DID in BfR to 31.6 ± 6.3 DID in DuR (<em>p</em> &lt; 0.001), and further to 37.6 ± 4.7 DID in AfR (<em>p</em> &lt; 0.01 vs. DuR). High-intensity statin consumption elevated by 115.9% in AfR compared to baseline (<em>p</em> &lt; 0.001). Prescribing of LLDs decreased from 12.5 ± 0.6 DID in BfR to 7.2 ± 1.2 DID in DuR (<em>p</em> &lt; 0.001), later reached 13.6 ± 3.8 DID in AfR (<em>p</em> &lt; 0.001 vs. DuR), with prescribing for ongoing users following similar trend. Expenditure on LLDs increased from €8.4 m ± 0.9 m in BfR to €11.4 m ± 2.0 m in DuR (<em>p</em> &lt; 0.001) and to €12.8 m ± 1.9 m in AfR (<em>p</em> &lt; 0.001 vs. BfR).</p></div><div><h3>Conclusions</h3><p>This study revealed a surge in consumption of LLDs in Turkey following the onset of the COVID-19 pandemic. This rise might be related to practices facilitating drug access, in addition to potentially greater adherence, or the necessity for more intense pharmacotherapy due to elevated cardiovascular risk.</p></div>\",\"PeriodicalId\":23949,\"journal\":{\"name\":\"Vascular pharmacology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2024-05-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vascular pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1537189124001083\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vascular pharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1537189124001083","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

背景:COVID-19 限制措施促使慢性病管理和生活方式的改变,可能会改变心脏代谢指标和降脂药物治疗模式。我们旨在评估 COVID-19 限制期间降脂药物(LLD)的使用趋势:我们从 IQVIA™ Turkey 获得了 2018 年 3 月 1 日至 2022 年 12 月 31 日的全国门诊药品销售和处方数据。我们评估了三个时期的 LLD 月平均消耗量、成本和季度处方水平:"限制前"(BfR,2018 年 3 月 1 日至 2020 年 3 月 31 日)、"限制期间"(DuR,2020 年 4 月 1 日至 2022 年 3 月 31 日)和 "限制后"(AfR,2022 年 4 月 1 日至 2022 年 12 月 31 日)。通过 "定义的日剂量/1000 居民/日"(DID)指标来衡量药物使用情况:结果:LLD 的使用量从 BfR 的 25.4 ± 3.1 DID 增加到 DuR 的 36.2 ± 6.8 DID(p 结论:LLD 的使用量从 BfR 的 25.4 ± 3.1 DID 增加到 DuR 的 36.2 ± 6.8 DID:这项研究表明,在 COVID-19 大流行后,土耳其的 LLD 消费量激增。这种增长可能与方便获取药物的做法有关,此外还可能与更高的依从性有关,或与因心血管风险升高而必须进行更严格的药物治疗有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Use of lipid-lowering drugs in restricted health access settings: Results from the Trends in Drug Utilization During COVID-19 Pandemic in Turkey (PANDUTI-TR) study

Use of lipid-lowering drugs in restricted health access settings: Results from the Trends in Drug Utilization During COVID-19 Pandemic in Turkey (PANDUTI-TR) study

Background

COVID-19 restrictions prompted changes in chronic disease management and lifestyle modifications, potentially altering cardiometabolic indicators and lipid-lowering pharmacotherapy patterns. We aimed to assess lipid-lowering drug (LLD) utilization trends during COVID-19 restrictions.

Methods

We obtained nationwide outpatient drug sales and prescribing data for 01.03.2018–31.12.2022 from IQVIA™ Turkey. We evaluated average monthly LLD consumption, their costs, and quarterly prescribing levels in three periods: “before restrictions” (BfR, 01.03.2018–31.03.2020), “during restrictions” (DuR, 01.04.2020–31.03.2022), and “after restrictions” (AfR, 01.04.2022–31.12.2022). Drug utilization was measured via “defined daily dose/1000 inhabitants/day” (DID) metric.

Results

LLD utilization increased from 25.4 ± 3.1 DID in BfR to 36.2 ± 6.8 DID in DuR (p < 0.001), and to 42.6 ± 5.3 DID in AfR (p < 0.001 vs. BfR). Statin consumption significantly rose from 22.0 ± 3.0 DID in BfR to 31.6 ± 6.3 DID in DuR (p < 0.001), and further to 37.6 ± 4.7 DID in AfR (p < 0.01 vs. DuR). High-intensity statin consumption elevated by 115.9% in AfR compared to baseline (p < 0.001). Prescribing of LLDs decreased from 12.5 ± 0.6 DID in BfR to 7.2 ± 1.2 DID in DuR (p < 0.001), later reached 13.6 ± 3.8 DID in AfR (p < 0.001 vs. DuR), with prescribing for ongoing users following similar trend. Expenditure on LLDs increased from €8.4 m ± 0.9 m in BfR to €11.4 m ± 2.0 m in DuR (p < 0.001) and to €12.8 m ± 1.9 m in AfR (p < 0.001 vs. BfR).

Conclusions

This study revealed a surge in consumption of LLDs in Turkey following the onset of the COVID-19 pandemic. This rise might be related to practices facilitating drug access, in addition to potentially greater adherence, or the necessity for more intense pharmacotherapy due to elevated cardiovascular risk.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Vascular pharmacology
Vascular pharmacology 医学-药学
CiteScore
6.60
自引率
2.50%
发文量
153
审稿时长
31 days
期刊介绍: Vascular Pharmacology publishes papers, which contains results of all aspects of biology and pharmacology of the vascular system. Papers are encouraged in basic, translational and clinical aspects of Vascular Biology and Pharmacology, utilizing approaches ranging from molecular biology to integrative physiology. All papers are in English. The Journal publishes review articles which include vascular aspects of thrombosis, inflammation, cell signalling, atherosclerosis, and lipid metabolism.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信